Partnerships and Licensing Agreements

ViaCyte has a number of key partnerships with world-class companies, providing us with important expertise and technologies to help us reach our important goals. In addition, our expanding know-how and intellectual property portfolio has the potential to provide cell therapies that expand well beyond the Company’s current focus in diabetes. As well, the expertise we are developing for effective delivery of cells, including the Encaptra® system, could be used in the development of a wide range of medical products. ViaCyte welcomes the exploration of research and business opportunities. Please contact us for further information.

Crispr Therapeutics

CRISPR Therapeutics

In 2018, ViaCyte formed a collaboration with CRISPR Therapeutics, a leading company in the gene-editing space focused on developing transformative medicines for serious human diseases. ViaCyte and CRISPR are collaborating on an exciting project to discover, develop, and commercialize gene-edited allogeneic stem cell-derived therapies for the treatment of diabetes. Together we are seeking to develop an immune-evasive stem cell line, derived from our well-characterized, regulatory compliant CyT49 line, as a first step on the path to a stem cell-derived product that can be used off-the-shelf without immune suppression.

Visit Website

W.L. Gore & Associates

W. L. Gore & Associates (Gore) is a global materials science company dedicated to transforming industries and improving lives. In 2017, ViaCyte and Gore announced a collaborative research agreement whereby the two companies work together to develop novel implantable cell therapy delivery device technologies that provide protection from immune rejection.

Nestle HealthScience

Nestle Health Sciences

Nestlé Institute of Health Sciences (NIHS) licensed stem cell technology from ViaCyte for basic research purposes. The NIHS is a fundamental research institute located on the campus of the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland with the primary mission of developing scientific expertise for the advancement of targeted medical nutrition approaches for disease modification and prevention.

Stemcell Technologies

STEMCELL Technologies

Under a license to certain ViaCyte patents, STEMCELL Technologies markets STEMdiffTM products for human embryonic and induced pluripotent stem cell differentiation.

Takara Bio

ViaCyte licensed to Takara Bio, Inc. certain portions of ViaCyte’s cell differentiation technology to expand Takara’s stem cell product line, marketed under the Cellartis® brand, for research purposes only.

Thermo Fisher Scientific

ViaCyte developed an advanced stem cell growth media that is licensed to Thermo Fisher, formerly Life Technologies, and marketed as StemPro® hESC SFM.


Fuji Film

Cellular Dynamics International holds a license to certain ViaCyte technology that is applied in the development and production of iCell® Hepatocytes which are human induced pluripotent stem cell-derived liver cells.